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Alzheimer’s disease (AD) is a common neurode-
generative disorder characterized by the deposi-
tion of amyloids in the brain. One prominent form
of amyloid is composed of repeating units of the
amyloid-b (Ab) peptide. Over the past decade, it
has become clear that these Ab amyloids are not
homogeneous; rather, they are composed of a ser-
ies of structures varying in their overall size and
shape and the number of Ab peptides they con-
tain. Recent theories suggest that these different
amyloid conformations may play distinct roles in
disease, although their relative contributions are
still being discovered. Here, we review how chemi-
cal probes, such as Congo red, thioflavin T and
their derivatives, have been powerful tools for the
better understanding of amyloid structure and
function. Moreover, we discuss how design and
deployment of conformationally selective probes
might be used to test emerging models of AD.
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Amyloid-b (Ab) is a short (38–42 residue) fragment of the amyloid
precursor protein. Under physiological conditions, Ab peptides adopt
a b-sheet-type secondary structure that is prone to self-assembly
into higher-order structures, including dimers, trimers, oligomers,
protofibrils, and the fibrils that are characteristic of patients with
late-stage Alzheimer's disease (AD). These conformations are
defined by their signature appearances by electron and atomic force
microscopy, their size on polyacrylamide gels, and even their
method of preparation (Figure 1). Collectively, these aggregates are
severely neurotoxic (1,2) and some of them also appear to inhibit
long-term potentiation and promote synaptic loss (3–5). The most
recent, emerging variants of the Amyloid Hypothesis propose that
the prefibrillar amyloids, such as oligomers and other soluble struc-
tures (Abeta-derived diffusable ligands (ADDLs), protofibrils, etc.),
might play a particularly central role in disease (6–9). However,
despite advances in our understanding of Ab biochemistry and AD
pathology, the mechanisms of neurodegeneration are still not clear.
One challenge is that amyloids, especially prefibrillar structures, are
structurally heterogeneous and conformationally dynamic, which has
complicated routine structural studies. Although progress has cer-
tainly been made using advanced methods, such as solid-phase
nuclear magnetic resonance (NMR) and computational simulations
(10–13), many important questions remain. What molecular features
do amyloids share? How do different amyloid conformers vary in
their topology? What are the mechanisms of neurodegeneration
and which specific features of amyloids contribute to toxicity?
These are clearly pressing questions, as more than 35 million peo-
ple suffer from AD and this afflicted population is expected to grow
rapidly without a clear disease-modifying therapeutic available.
Small molecules that bind to amyloids, such as the widely used thio-
flavin T (ThT) and Congo red (CR), have been essential tools in the
study of Ab aggregation. In part, the strength of these compounds is
their versatility; they have been used to monitor self-assembly in vi-
tro, to recognize Ab deposits in vivo and to identify aggregation inhib-
itors. In addition, these compounds have been used to probe the
structure of various amyloids, and these studies have provided
insights into the molecular features of the binding sites. Here, we
review what is known about the binding of small molecules to amy-
loids and summarize what these studies have revealed about the rela-
tionships between amyloid structure and function.
Thioflavin T
Binding to aggregated Ab enhances ThT
fluorescence
Thioflavin T is a benzothiazole-based dye (Figure 2A) first noted to
bind amyloid by Vassar and Culling in 1959 (14) and later used in
studying patient-derived amyloids by Naiki et al. (15–17). These
groups noted that the fluorescence of ThT is quenched in solution,
but that its quantum yield is greatly increased when bound to the
b-sheet structure of amyloid fibrils (18). This same phenomenon
was observed with synthetic Ab fibrils (19), and ThT was adapted
by LeVine (20) into a convenient, inexpensive assay for monitoring
fibril formation in vitro. This protocol has been largely unchanged
and is perhaps the most widely employed method for monitoring
Ab aggregation.
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Thioflavin T fluorescence is thought to increase when bound to Ab
fibrils because of the changes in the rotational freedom of the
carbon–carbon bond between the benzothiazole and aniline rings
(Figure 2A) (18,21,22). In the unbound state, the ultrafast twisting
dynamics around this bond are thought to cause rapid self-quench-
ing of the excited state, resulting in low emission. However, upon
binding to fibrils, the rotational freedom is apparently restricted and
the excited state is readily populated. This concept was recently
confirmed using a series of synthetic ThT analogs, which varied in
their flexibility (22). The practical outcome of this mechanism is that
ThT and its analogs can be used to spectroscopically quantify the
amount of amyloid in a sample.
Binding modes of ThT to amyloid fibrils
The dramatic response of ThT's fluorescence to amyloids suggests
that a defined binding event takes place to restrict the motion of
the compound. Thus, studying this interaction would be expected
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Figure 2: Thioflavin T (ThT) binds amyloids at multiple sites. (A) Chemical structures of ThT and a neutral analog, BTA-1, highlighting the major components:
a benzothiazole ring system attached to functionalized aniline. The linker between these modules is shown in red. (B) Amyloids contain three distinct ThT bind-
ing sites, two with high density (BS1 and BS2) and one with low density (BS3). (C) Snapshots from molecular dynamics simulations illustrate ThT binding within
two channels lined with either Phe residues (left) or both Phe and Val residues (right) (27,28). (D) A schematic model of the two ThT binding sites, illustrating












Figure 1: Amyloid-b self-assembles into a variety of distinct conformations. Monomers assemble into dimers, trimers, and other low-molecular-weight oligo-
mers, which proceed to form larger oligomers and protofibrils. Mature fibrils have a characteristic, elongated morphology. Electron micrographs of enriched sam-
ples are shown.
Reinke and Gestwicki
400 Chem Biol Drug Des 2011; 77: 399–411
to reveal insights into the local amyloid topology and its molecu-
lar features. This strategy has been productive, with solid-state
NMR (10), radiolabeling (23,24), competition assays (25), and
molecular dynamics (MD) simulations (26–28) all having been
used to evaluate ThT binding to amyloids. One of the first impor-
tant observations was made by LeVine (25), who proposed that
there are multiple binding sites for ThT on amyloids. Lockhart
et al. (23) further refined this model using fluorescence and radio-
label-based assays. Together, these studies suggested the pres-
ence of three distinct binding sites (BS1, BS2, and BS3) on Ab
fibrils. Sites BS1 and BS2 are relatively abundant, with approxi-
mately one site per 4–35 Ab monomers (Figure 2B). The less-
abundant site, BS3 is found at approximately one site for every
300 monomers. Based on Forster resonance energy transfer mea-
surements, binding sites BS1 and BS2 are thought to be in close
proximity; however, occupancy was found to be neither coopera-
tive nor competitive.
Further insights into how ThT binds in these different sites was
supplied by MD simulations (27,28). Briefly, Wu et al. (27) simulated
ThT binding to protofibrils composed of Ab (16–22) and character-
ized the formation of three unique, populated clusters. Consistent
with their earlier findings (28), the least populated binding cluster
was located at the end of the protofibril in an orientation anti-par-
allel to the fibril axis. The two other clusters were more heavily
populated and located parallel to the fibril axis (anti-parallel to the
b-sheet). Together, these results seem to confirm Lockhart's model
of two high-density ThT sites (BS1 and BS2) and a single low-den-
sity site (BS3) (Figure 2B). In this model, BS1 and BS2 are com-
posed of surface grooves created by aligned side chains in the
fibril axis, which provide much of the binding energy. When bound
in these grooves, MD simulations suggest that the ring systems
adopt a planar organization, with the charged nitrogen exposed to
solvent (26,29) (Figure 2C). Interestingly, similar grooves have been
proposed in amyloid fibrils composed of many different proteins
(e.g. a-synuclein and prions), which may explain why ThT fluores-
cence is also sensitive to other, unrelated amyloids. However,
because different amyloid-forming peptides do not share a high
sequence identity, these results also suggest that some degenera-
tive feature(s), such as hydrophobicity or contacts with the peptide
backbone, are responsible for ThT binding.
Consistent with this idea, a closer examination of the molecular
models reveals interesting features of the two most populated ThT
binding sites (Figure 2C) (27). These two binding channels are lined
with at least five, spatially consecutive, hydrophobic (Phe only or
Phe and Val) side chains, which are located on opposite 'faces' of
the amyloid structure. Similar findings have been observed by Koide
et al., who developed peptide self-assembly mimics that have
repetitive, b-sheet amyloid-like structure (30–32). These soluble
model proteins are amenable to crystallization, and co-crystals with
bound ThT revealed that the compound binds in channels lined with
five or six aromatic and hydrophobic side chains (31). Interestingly,
it is critical that the favorable, hydrophobic residues within the
channel are spatially consecutive, as two adjacent clusters of Tyr
residues separated by a Lys and Glu showed no ThT binding (31).
Collectively, these observations converge on a model in which five,
aligned aromatic and ⁄ or hydrophobic residues are critical for ThT
binding, while the exact identities of the side chains appear to be
less important than their overall hydrophobicity.
An alternative binding mode was suggested by Groenning et al.
using spectroscopy and molecular modeling to examine ThT binding
to insulin fibrils. Although they confirmed that at least two distinct
binding sites exist, with ThT binding predominantly parallel to the
fibril axis (33,34), they further suggest that two ThT molecules in
an excited-state dimer, or 'excimer,' form might bind to the grooves.
Thus, a higher-order form of ThT, even as large as a micelle (35),
might be involved in binding under some conditions and for some
amyloids.
ThT also recognizes prefibrillar Ab aggregates
As mentioned previously, prefibrillar intermediates are now thought
to correlate with neurodegeneration, which has prompted interest
in evaluating ThT binding to these structures. In the literature, there
was initially debate over whether ThT binds oligomers and protofi-
brils. In fact, several groups initially defined ThT as a fibril-specific
probe (36–39). However, methods for preparing prefibrillar struc-
tures have become more reliable, and comprehensive studies have
now noted clear changes in fluorescence when ThT is added to
prefibrils (40–42). For example, Walsh et al. (42) prepared samples
of protofibrils and observed that they produce a concentration-
dependent increase in ThT fluorescence. The binding of ThT to
prefibrils is consistent with the binding information discussed ear-
lier, as these structures are known to be rich in the hydrophobic,
b-sheet content important for binding (42). For example, models of
Ab protofibrils have the requisite stretch of aligned hydrophobic
residues one might expect to form the high-abundance ThT-binding
site (43). However, fibrils and prefibrils are not identical in their
binding to ThT, as many groups have noted that the maximum fluo-
rescence induced by prefibrils is less (per mole of Ab) than that
stimulated by fibrils. For example, ThT fluorescence is modestly
increased (1.5-fold) in the presence of Ab oligomers (41) of either
1–40 or 1–42 Ab (40), while fibrils often yield over 100-fold
improvements in fluorescence (44). Moreover, using surface plasmon
resonance (SPR), ThT (Kd = 498 nM) was shown to bind Ab oligo-
mers, but the total number of bound molecules was significantly
less than in fibrils (40). These observations and others are likely
consistent with other findings, because protofibrils are proposed to
be more dynamic (45) and contain relatively fewer ThT-binding sites
(46,47).
Interactions of ThT analogs with Ab
Additional insights into the nature of the ThT-binding groove can be
gained from studying synthetic ThT derivatives in which the molecu-
lar features of the molecule are systematically varied. In general,
these derivatives are composed of a benzothiazole ring system
attached to a substituted aniline (Figure 2A). Derivatives of this
scaffold tend to have modifications at the amine of the aniline and
at positions around the benzothiazole. Fortunately, many analogs
have been explored as part of studies to develop imaging agents
and; in many cases, the binding affinity of these compounds for
amyloids has been reported. For example, Klunk et al. (48) synthe-
sized several neutral ThT analogs, such as BTA-1, to explore the
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effect of the positive charge on the benzothiazole ring (Figure 2A).
They found that each neutral analog bound better to Ab than ThT,
with the best having a 40-fold improved affinity. These findings
suggest that the positive charge in ThT may be detrimental for
binding, which is a model supported by MD simulations indicating
that the neutral BTA-1 is able to bind deeper into the hydrophobic
binding grooves (27). However, ThT does not entirely compete with
BTA-1 for binding (25), and Lockhart et al. (23) observed different
binding patterns between the two ligands. In silico data further
reveal that the ring systems of BTA-1 are planar in the bound orien-
tation, instead of in a slightly twisted orientation, as observed with
the charged ThT scaffold (27). Collectively, these data support a
model in which some of the 'ThT binding sites' (i.e. BS1, BS2 and
BS3) are more favorable for ThT, while others prefer neutral
ligands. Interestingly, removal of the positive charge does not seem
to affect oligomer binding, suggesting that one of the binding sites
may be more prevalent in prefibrils (49). One possibility is that
some of the sites allow deeper binding grooves, perhaps permitting
neutral ligands with increased access. This idea is supported by
measurements of the dimensions of the two sites identified by
modeling: one has an average depth (backbone to solvent) of 5.4 ,
while the other is 7.1 . This deeper site might allow better pene-
tration of neutral derivatives and, consequently, more favorable bur-
ied surface area and better affinity. These sites are unique in other
dimensions as well; the shallower site is wider (17 ), while the
deeper site is narrower (10 ). It is not yet clear which site is BS1
or BS2, but these differences support the model that the two sites
have distinct properties. To our knowledge, structure-guided design
has not yet been used to rationally exploit these differences.
Synthetic ThT derivatives have also been useful in further refining
the features of the binding sites. For example, the benzothiazole
can be replaced by a roughly planar benzofuran, imidazo-pyridine,
imidazole, or benzoxazole core, without impacting affinity (49–52).
Additionally, the aniline may be replaced with other flat, rigid moie-
ties (e.g. stilbene and cyanobenzyl) without significant consequence
(53,54). Insertion of a planar styrene group between the benzothiaz-
ole and aniline is also well tolerated (53), while some substitutions,
such as bithiophenes, even improve affinity (55). In addition, these
substitutions need not be aromatic, because methyl-piperazine
groups appended to the aniline are tolerated (56). Interestingly,
some of these substitutions extend the end-to-end distance of the
ThT-like molecule by over 25%, suggesting that the binding channel
can accommodate relatively long molecules, as long as they are
planar and hydrophobic. However, there are limitations to the size
of this channel, because installation of a large, freely rotatable rhe-
nium chelate to the aniline abolishes binding (57). Appending the
same group to the opposite end of the molecule actually enhanced
binding by eightfold, which suggests that the dimensions of the
channel are limited in some regions.
More subtle substitutions to the benzothiazole and aniline groups
also help define the nature of the ThT binding site(s). For instance,
the di-methyl amine group can be moved to the benzothiazole on
the opposite side of the molecule without any consequence to bind-
ing affinity (58), suggesting that ThT derivatives may be able to
bind in either orientation (Figure 2D). However, small alkyl-type sub-
stitutions in key positions appear to impact the binding mode (59).
For example, a methyl group at the six-position of the benzothiazole
ring is favored only if no methyl substitutions are present on the
amine of the aniline (Ki = 9.5 nM). Alternatively, two methyl groups
on this amine were favored if the six-position was hydrogen
(Ki = 4 nM). Interestingly, a more polar, hydroxyl at the six-position
was tolerated only if the aniline was substituted with at least one
methyl group, suggesting that overall hydrophobicity is a critical
element for binding.
In summary, multiple experiments have converged on a model in
which amyloids contain up to three different binding sites. The two
major sites (BS1 and BS2) are parallel to the fibril axis and are sensi-
tive to relatively modest increases in steric size in some positions,
while they can be readily elongated in the channel if overall planarity
is maintained (Figure 2D). The major contacts with ThT are through
aromatic and ⁄ or hydrophobic side chains in the parallel groove, and
neutral derivatives bind tighter than their charged counterparts. It is
important to note that BS1 and BS2 are present in roughly equivalent
numbers (at least on fibrils) and that the experiments discussed here
often focus on the composite affinities. Differences in the way that
ThT derivatives bind the different sites might easily be masked in
these studies and, moreover, little is likely learned about the require-
ments at BS3 in these types of experiments.
Congo Red
CR binds at least two sites on amyloids
Congo Red staining serves as a positive indicator of amyloid depo-
sition, and its optical properties have been extensively reviewed
(60,61). Briefly, CR selectively stains amyloid in vitro and in brain
slices, and bound material displays a characteristic birefringence
under polarized light. Like ThT, binding is observed with both Ab-
derived amyloids and amyloids derived from other peptides, sug-
gesting that shared elements, such as b-sheet structure or peptide
backbone, are involved in binding. Consistent with this idea, molec-
ular docking simulations suggest that CR binds one site parallel to
the fibril axis (anti-parallel to the b-sheets) (62) on amyloid fibrils
(28,63,64) and protofibrils (28). Based on the approximate length
one of the CR molecule (19 ) (Figure 3A), Klunk et al. (62) pro-
posed a model in which it requires at least five Ab monomers for
binding. Lockhart et al. further characterized the number and types
of CR-binding sites using a close analog, BSB (24). These studies
revealed two non-equivalent binding sites, one of which is shared
by ThT and is present at one site per three Ab monomers. More-
over, the shared binding site was found to be the highest-density
ThT binding site (BS2) (Figure 3B). These findings clarify the seem-
ingly contradictory, earlier observations that CR and ThT have dis-
crete binding sites (56), while other groups have reported
competition (25,65). To keep consistent with the existing nomencla-
ture and as a useful tool for discussion in this review, we identify
the unique CR-binding site as BS4. Insight into the nature of BS4
came from studies on a prion-derived, amyloidogenic peptide with
the sequence GNNQQNY (28). Specifically, MD simulations revealed
that CR favors binding parallel to the fibril axis (anti-parallel to the
b-sheets), but that it also populates a second site at the 'end' of
the protofibril in an orientation anti-parallel to the fibril axis
and parallel to the b-sheets (Figure 3C). This latter mode only
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represented approximately 11% of the total CR binding clusters,
while the anti-parallel orientation was clearly preferred (78% of the
total binding). This model perhaps explains the difference between
CR binding affinity (Kd high nM ) low lM) and its inhibition capac-
ity (IC50 mid-high lM). In other words, CR may preferentially bind
anti-parallel to the b-sheet, but this binding mode is not likely to
inhibit fibril extension. When BS2 becomes saturated, CR may bind
BS4 at the face of the growing fibril, only then disrupting monomer
acquisition and elongation.
Similar to ThT, the main CR binding mode appears to be defined by
a channel formed from side chains. The CR-binding channel is
longer (23–25 ) and narrower (5–8 ) than the ThT channels,
although it must include a portion of ThT-binding BS2 site based on
the competition results. However, in contrast to the ThT channel,
the residues that line the CR-binding site are largely polar and non-
aromatic, such as Asn and Gly. In addition, despite the presence of
nearby tyrosines, these aromatic residues do not appear to partici-
pate in CR binding (Figure 3C, left). Instead, in three of the four
most populated clusters, the sulfonic acid moieties were aligned
with the N-terminus, the only positive charge on the specific pep-
tide used in these experiments (Figure 3D). These data suggest that
ionic or polar interactions may be important for CR binding. Even
greater detail has been provided by molecular docking of CR to 20
A Chemical structures of CR and its related 
natural and synthetic analogs
C CR access two binding modes relative to the β-sheet
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Figure 3: Congo red (CR) accesses two distinct binding sites on amyloids. (A) Structures of CR and its analogs. (B) The two CR binding sites on amyloid are
shown, one with high density (BS2) and the other with low density (BS4). (C) Model of the high-density site, parallel to the fibril axis, and the low-density site
at the end of the fibril. In the high-density site (BS2), the channel is largely composed of polar, uncharged residues. (D) Close-up of the BS2 site, highlighting
the interaction with the charged sulfonic acid at the end of the CR molecule. Adapted from (28). (E) Schematic model of bound CR in the BS2 site, with the
molecular dimensions and features shown.
Amyloid Structure Using Chemical Probes
Chem Biol Drug Des 2011; 77: 399–411 403
NMR structures (66) composed of near full-length Ab (9–40) (67).
These results confirmed two distinct CR binding sites, one located
near Lys28 and the other at the C-terminus, making contacts with
Asn27 and Val39. This is one of the first studies to implicate spe-
cific residues of the Ab peptide in CR binding and, further, the con-
tacts with Lys28 and Asn27 were confirmed by mutagenesis.
Accordingly, these results suggest that, in the context of full length
Ab, Lys28 may provide the requisite positive charge to interact with
the sulfonic acids. Thus, the identity of the side chains seems to
play less of a role than polar contacts at the termini of the pocket.
CR binds prefibrillar amyloids
The first indication that CR may recognize prefibrils was by Walsh
et al., (42) who showed that CR absorbance was altered by Ab pro-
tofibrils. In addition, CR and BSB have been found to bind globular
Ab oligomers (Kd = 3.2–19.5 lM) by SPR (40). Interestingly, solu-
tion-state NMR has recently revealed that CR binds low-molecular-
weight Ab species as well (68). It is not yet clear whether the fun-
damental features of the CR binding site(s) on early Ab oligomers
are similar to those defined for fibrils. However, similar to what
has been observed with ThT, the absolute number of binding sites
appears to be reduced compared with fibrils.
CR analogs reveal features of the amyloid-
binding sites
Synthetic CR derivatives have provided further insight into the fea-
tures of the binding sites on amyloids. For example, early analogs
explored the requirements for the sulfonic acids (62). Using a radio-
labeled displacement assay, Klunk et al. (62) identified that other
charged groups, such as carboxylic acids, could replace the sulfonic
groups. More recent studies found that the carboxylates were not
absolutely required if phenolic hydroxyls were included (69). Further
structure–activity relationship studies revealed that the methoxy
substitutions that are located on some CR analogs are expendable
(56,70); thus, there are likely no specific contacts made with those
groups.
In addition to the contacts at the termini, the overall planarity of
the molecules appears to be critical to their binding. Effective CR
analogs, including X34 (71), BSB (72), K114 (73), IMSB (56), and
methoxy-X04 (74), are all aromatic and planar and they seem to
share binding sites (73) (Figure 3A). Other derivatives, based on the
curcumin scaffold, revealed that two terminal aromatics are neces-
sary (70). Interestingly, the overall size of the molecule was found
to follow strict requirements, with the linker length restricted to 8–
16  and including no more than 2–3 rotatable bonds. This general
conclusion is supported by studies that indicate the more rigid enol
form of curcumin is favored to bind Ab, relative to the more flexi-
ble keto form (75,76). Together, these findings are consistent with a
model in which the binding site for CR has limited size, with a
hydrophobic channel and polar (or positively charged) groups at the
ends (Figure 3D). These same molecular contacts may be equally
crucial in prefibrillar conformations, because curcumin also inhibits
the formation of low-molecular-weight (LMW) and oligomeric Ab
(77).
Peptides
The hydrophobic core region (HCR) is critical
for Ab aggregation
The HCR of Ab spans residues 16–20 (KLVFF) and is thought to
be one of the most critical elements for Ab self-assembly (Fig-
ure 4A). This model arose from experiments, such as those
reported by Tjernberg et al., (78) in which they tested binding of
Ab peptides to full-length Ab (1–40) and found that only three
truncations (residues 10–19, 11–20, or 12–21) were capable of
significant binding. Further studies showed that systematic substi-
tution of the hydrophobic residues 17–20 in Ab (10–42) for more
hydrophilic amino acids reduces fibril formation (79). Moreover,
point mutations in Val18, Phe19, and Phe20 are sufficient to block
aggregation (79,80), suggesting that these residues play a particu-
larly important role. Further, the hydrogen-bond network associated
with the amide backbone of KLVFF is critical in determining aggre-
gate morphology (81). Together, these findings suggest that the
HCR, and especially KLVFF, may be an attractive target for probe
development.
KLVFF motifs are aligned in Ab fibrils and free
sites are available at the ’ends’
Mature fibrils have a largely parallel b-sheet structure, such that
the residues in this region are aligned (e.g. Phe 19 from one strand
is stacked against Phe 19 from the next monomer) (Figure 4B). Even
in prefibrillar samples, which contain both parallel and anti-parallel
b-sheets (82,83), KLVFF regions are thought to be partially aligned,
especially at the core Phe19 residue (84,85). These observations
suggest that free KLVFF peptides will tend to align with their corre-
sponding residues in both prefibrillar and fibrillar amyloids. Consis-
tent with this idea, early structure–activity studies revealed that
the peptides KLVFF, QKLVFF, HQKLVFF, KLVFFA, KLVFFAE, and
QKLVFFA bound with the best affinity to Ab (1–40) fibrils (86). This
hypothesis was later confirmed using 38 fluorescently labeled 5-
mer fragments (87). Interestingly, Ma and Nussinov (63) found that
KLVFF interacts within Ab oligomers in two orientations; one in
which KLVFF binds its identical, homologous residues on the neigh-
boring molecule, and other in which this directionality is reversed
and shifted (Figure 4C).
Another critical feature of the KLVFF-binding site is that it will be
exposed at the 'ends' of aggregates (Figure 4D). Indeed, extensive
hydrogen–deuterium exchange (HDX) and solution-state NMR stud-
ies have shown that these residues are poorly solvent accessible in
the core of fibrils (83,88,89) while they are more exposed in prefibr-
illar species. For example, only Leu17 and Val18 within the HCR are
buried in LMW Ab and only Leu17, Val18, and Phe19 In globular
oligomers (88). Thus, opposite to what was discussed for the ThT-
and CR-binding sites, there may be more KLVFF-binding sites in
early amyloid species (11). Moreover, in the context of this review,
these observations are of particular interest because they suggest
that KLVFF-based probes might be used to understand the chemical
and structural environment around the free 'ends' of amyloids. As
discussed earlier, ThT- and CR-like ligands populate this region (BS3
and BS4), but with low abundance and weak affinity.
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Interactions of KLVFF derivatives with Ab
Because the natural KLVFF sequence aligns with itself in amyloids,
structure–activity studies on modified peptides can be used to
probe the structural requirements in this region. For example,
Cairo et al. (90) used SPR to determine the affinity of 24 KLVFF-
based ligands for fibrils. They discovered that KLVFF has a low
binding affinity (Kd = 1.4 mM), consistent with its inability to inhi-
bit aggregation (91,92). The specific requirement for aromatic side
chains was demonstrated by the 10-fold loss in affinity upon
removal of the terminal Phe residue and the threefold loss in
affinity upon replacement of Phe with His residues (KLVFH and
KLVHH). In contrast, systematic substitution of the Phe residues
for Tyr (KLVYF and KLVFY) did not dramatically alter affinity
(Kd = 1.6–2.4 mM). However, there appears to be limits to these
substitutions because introduction of a Trp residue (KLVFW) or two
Tyr residues (KLVYY) was not well tolerated. Interestingly, the all
D-KLVFF stereoisomer shows no difference in binding affinity
(90,93), suggesting that the identity and order of the residues is
more important than their position relative to the backbone. Con-
sistent with this idea, substitution of the amide bond with either
ester or N-methyl groups has little effect (94–96). Collectively,
these findings suggest that the side chains of KLVFF are critical
for recognition, but that the backbone does not significantly partic-
ipate in binding of free peptide.
Although the core KLVFF sequence itself is somewhat sensitive
to relatively minor changes, additions to either end seem well
tolerated. For instance, appending polar residues, including
stretches of lysines or arginines (KLVFFK4, KLVFFK6, and KLVFFR6)
significantly improves affinity (Kd = 37–80 lM) (90). It seems likely
that these residues make favorable contacts with residues adja-
cent to the HCR to add additional binding energy. Further, the
addition of the lysines was preferred on the C-terminal end of
the molecule, as KLVFFK4 displayed nearly a fivefold better
affinity than K4LVFF. Similarly, addition of bulky moieties to the
N-terminus of KLVFF are tolerated, and, in some cases, improve
recognition. For example, replacement of the lysine of KLVFF with
a sterol had no effect on Ab binding (97) and Gordon et al. (96)
showed that an N-terminal anthranilic acid improves binding five-
fold.
Together, these studies lead to a model in which KLVFF binds to
sites at the ends of amyloids in either a parallel or anti-parallel
mode (Figure 4E). The side chains, specifically the Phe residues,
predominantly drive binding, with little contribution from the pep-
tide backbone. Further, polar and non-polar groups could be
appended to KLVFF to enhance its binding. In this regard, KLVFF
may be a useful 'anchor' molecule for probing the surrounding
regions at the ends of Ab aggregates.
H N-DAEFRHDSGYEVHHQ-KLVFF-AEDVGSNKGAIIGLMVGGVVIA-COOH2A Amyloid-β (1–42)
C KLVFF binds Aβ in multiple orientations 
E Phenylalanine contacts drives KLVFF binding 
B Residues in the HCR align within Aβ fibrils 
D KLVFF binds its homologous 

















Figure 4: KLVFF bind at the exposed 'ends' of amyloid-b (Ab) aggregates. (A) The sequence of Ab (1–42), with the HCR highlighted in green. (B) The side
chains of the KLVFF (colored) align within the stacked b-sheets of fibrils, leaving one motif free at each end. (C) KLVFF interacts with amyloids in two orienta-
tions; either the homologous residues align (left) or the sequence is reversed and shifted (right). The parallel mode is favored in fibrils, while the anti-parallel
orientation predominates in non-fibrillar oligomers. Regardless, Phe-Phe contacts seem to be crucial for binding. (D) Model of KLVFF aligned with its cognate
sequence in a fibril. Adapted from solid-state NMR structures (PDB:2BEG) (13). (E) Schematic model illustrates that KLVFF binds at the ends of fibrils and smal-
ler oligomers (inset), with Phe residues being critical to the assembly. In smaller oligomers, KLVFF might bind anti-parallel to its cognate sequence.
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Conformation-Specific Probes
Ab assembles into amyloids with a variety of
distinct conformations
Extensive NMR (83,98,99), microscopy (100–102), HDX
(45,83,88,103), Fourier-transform infrared spectroscopy (82,104), sta-
bility measurements (105), and MD (11,63) studies have suggested
that Ab can form multiple types of amyloid structures, including
LMW (e.g. dimers, trimers, etc.) structures, soluble oligomers, pro-
tofibrils and fibrils. These structures differ in their overall size,
shape, and the number of monomers they contain. In addition, a
major theme in recent reports is that fibrils tend to be densely
packed, while prefibrillar conformations are 'looser' or more
dynamic in structure. For example, Wetzel's group showed that the
core of Ab fibrils is extremely resistant to solvent exchange (103),
while Qi et al. (45) demonstrated that oligomers incorporate deute-
rium at a rate 10-fold greater than fibrils. These types of studies
have also carefully mapped the residues in oligomers that are most
accessible (83,88). Based on these structural differences, it seems
likely that small molecules might be able to exploit the unique
structural features that differentiate conformers. Consistent with
this idea, numerous studies have reported small molecules that spe-
cifically block the formation of one type of amyloid conformation,
without impacting others (106–109).
Conjugated polymers respond to Ab
conformation
Nilsson et al. and Hammarstrom et al. have performed pioneering
studies using luminescent-conjugated polymers (LCPs) to selectively
detect amyloids (110–114) (Figure 5A). When these polymers engage
their target, they are designed to adopt a backbone orientation that
conforms to the size and shape of the bound structure. This re-
arrangement aligns the polymer scaffold and alters the apparent fluo-
rescence properties, yielding an 'optical fingerprint' specific to the
bound amyloid. Using multiphoton microscopy, deposits in brain tissue
have been labeled with several LCPs, revealing the presence of multi-
ple, optically unique morphologies within a single plaque (113).
Recent studies by these groups have also revealed smaller, pentamer-
ic thiophene derivatives (Figure 5A) that retain conformation-selective
spectral binding properties (111). Included in these novel derivatives
is the anionic ligand p-FTAA, which recognizes prefibrillar Ab species
in vitro and labels Ab deposition in transgenic mouse models, indicat-
ing that these BBB-permeable derivatives may be informative for
monitoring distinct conformations in vivo (111,112). It remains unclear
precisely which Ab conformations are bound by these probes or
which ones correlate best with the toxic species. However, these find-
ings do suggest that distinct amyloid morphologies co-localize in dis-
eased brain tissue.
Indoles selectively detect prefibrillar amyloid
We recently reported an unbiased screening approach to identify
compounds that interact with prefibrillar, but not fibrillar, amyloids
(105,115). These efforts identified indole-based compounds that only
undergo a change in fluorescence in the presence of prefibrillar
structures, with a selectivity coefficient nearly 20-fold greater than
ThT (Figure 5B). By optimizing the chemical structure of the indole
and the reaction conditions (e.g. buffer and time), one promising
probe, tryptophanol (TROL), was developed into a 'ThT-like' spectro-
scopic assay for prefibrillar amyloids (115). These findings suggest
that some of the indoles access a site on prefibrillar Ab that likely
becomes buried or otherwise inaccessible upon fibril formation.
































































Figure 5: Chemical structures of some conformationally selective amyloid-b probes. The structures of various, reported molecules are shown. See the text
for details.
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probes further demonstrate that prefibrillar and fibrillar amyloids
have different molecular features that can be exploited by small
molecules.
Selective Ab probes based on peptides
In addition to screening approaches, rational design has been used
to develop conformationally sensitive probes. For example, Hu et al.
(116) developed a peptide-based probe, PG46, in which a portion of
the Ab (1–40) was replaced with a binding epitope for the fluores-
cent dye, FLaSH (Figure 5C). When this modified peptide was added
to different amyloids, they found that its fluorescence was only sen-
sitive to intermediate aggregates (e.g. oligomers), but not LMW or
fibrillar amyloids, likely because of differences in the local environ-
ment of the fluorophore. In addition, we recently developed bivalent
KLVFF derivatives that specifically bind LMW trimers and tetramers
of Ab (117) (Figure 5D). Using molecular modeling, we estimated the
distances between exposed KLVFF binding sites on the 'ends' of Ab
dimers, trimers, and tetramers. Then, corresponding ligands were
assembled by solid-phase peptide chemistry with L-amino acids and
a biotin tag was incorporated. Using polyacrylamide electrophoresis,
we found that the bivalent KLVFF probes bound primarily to the tri-
mer and tetramer, with some binding to dimer. These findings are
consistent with recent MD simulations, which suggest that the Ab
(9–42) dimer is highly dynamic and may exist in orientations that are
distinct from other conformations (11). In addition, no binding to
monomers or higher-order oligomers was observed. Although in its
infancy, the field of conformational selective probes holds promise in
understanding amyloid structure and function.
Conclusions and Prospectus
Classic amyloid probes like ThT and CR have played a key role in
our understanding of amyloid structure. As the appreciation of the
number of different conformations has broadened, these scaffolds
have found exciting, new roles. However, the classic probes tend to
have relatively poor selectivity. Thus, the development of next-gen-
eration ligands will be an important step in further accelerating our
understanding of the roles of amyloids in disease. Toward that goal,
one approach that might be particularly fruitful is the use of multi-
valent ligands. The synthesis of bivalent, 'molecular tweezers' that
bind amyloids have been reported (92,93,117–121), and we expect
that these types of scaffolds may be incorporated into the next bat-
tery of tools. In turn, these designed ligands might be used to ask
the next generation of questions about amyloid structure and func-
tion. Where are the small molecule-binding sites positioned in rela-
tion to one another? How does the position or number of these
sites change upon transition from one conformation to another? A
combination of old and new chemical probes will likely be neces-
sary to answer these questions and others.
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